Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorp
Markets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to Q4 results and news developments. Hero MotoCorp reported strong Q4 earnings, while L&T saw a profit decline but recommended a dividend. Bharti Airtel is exploring network slicing for premium services.
Bharti Airtel explores 5G network slicing for premium plans
Bharti Airtel is exploring network slicing. This technology will allow for premium voice and data plans. It aims to monetize its 5G infrastructure. This move follows rival Reliance Jio's enterprise use-case plans. Network slicing creates virtual networks for specific needs. This could boost retail and enterprise offerings.
How Wipro's Rs 15,000 crore share buyback offer can give double-digit returns in weak market
Wipro announced a Rs 15,000-crore share buyback at Rs 250 per share, offering a 22% premium. Retail investors could see returns of 11-13% with an expected 50-60% acceptance ratio. This tender route buyback, the first in three years, reserves 15% for small shareholders, potentially boosting their returns significantly.
Wipro share buyback: IT major announces Rs 15,000 crore offer at 19% premium. Key things to know
Wipro share buyback: IT services giant Wipro announced a significant Rs 15,000 crore share buyback at Rs 250 per share, a 19% premium over the last closing price. This marks the company's first buyback in over three years, involving up to 60 crore shares, representing 5.7% of its paid-up capital. Promoters have indicated their intention to participate in the tender route buyback.
Aurobindo Pharma approves ₹800 crore share buyback; Check premium, record date and more
This is Aurobindo Pharma's first share buyback in nearly two years. Back in August 2024, the company had announced the repurchase of 51.36 lakh equity shares at a price of ₹1,460 apiece. The drugmaker had spent ₹750 crore for this buyback, which was also carried out via the tender offer route.